Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiangya School of Medicine, Central South University, Changsha, 410078, Hunan, China.
Curr Mol Pharmacol. 2024;17(1):e210823220109. doi: 10.2174/1874467217666230821142839.
Osteosarcoma is the most common primary bone malignancy and has a high tendency of local invasion. Although a lot of studies have focused on chemotherapy and combination chemotherapy regimens in recent years, still, there is no particularly perfect regimen for the treatment of relapsed or metastatic OS, and the prognosis is still relatively poor. As a new therapeutic method, targeted therapy provides a new scheme for patients with osteosarcoma and has a wide application prospect. This article reviews the latest progress of targeted therapy for osteosarcoma, and summarizes the research on the corresponding targets of osteosarcoma through six major pathways. These studies can pave the way for new treatments for osteosarcoma patients who need them.
骨肉瘤是最常见的原发性骨恶性肿瘤,具有高度局部侵袭性。尽管近年来有大量研究集中在化疗和联合化疗方案上,但对于复发性或转移性骨肉瘤的治疗仍没有特别完美的方案,预后仍相对较差。作为一种新的治疗方法,靶向治疗为骨肉瘤患者提供了新的方案,具有广泛的应用前景。本文综述了骨肉瘤靶向治疗的最新进展,通过六大途径总结了骨肉瘤相应靶点的研究,为有需要的骨肉瘤患者的新治疗方法铺平了道路。
Curr Mol Pharmacol. 2024
JBI Database System Rev Implement Rep. 2017-8
Cochrane Database Syst Rev. 2018-2-6
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2014-7-1
Pharmaceuticals (Basel). 2025-4-3
J Cancer Res Clin Oncol. 2024-8-22
Cancer Rep (Hoboken). 2024-8